May 20, 2021 in Featured, Press Releases

XPhyto Rapid Point-of-Care COVID-19 PCR Test Offered for Sale in Germany

• Rapid 25-minute point-of-care COVID-19 PCR test available for purchase in Germany commencing May 25, 2021
• Volume based pricing competitive with other COVID-19 PCR test products on the market
• Initial manufacturing capacity secured, additional capacity to increase based on demand

Vancouver, Canada, and Memmingen, Germany (May 20, 2021) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that its distribution, storage and logistics partner, Max Pharma GmbH (“Max Pharma”), will launch the sale of its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”) in Germany next week. Covid-ID Lab is registered within the European Union as a commercial in vitro diagnostic (CE-IVD) test.

Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction. Following the RT-PCR process, the SARS-CoV-2 virus is detected on a test chip and the results can be read visually within 5 minutes, combining the speed of an antigen test with the accuracy of a PCR test.

“Covid-ID Lab provides diagnostic level accuracy in minutes at the point-of-care. It is a specialized product that is designed to fill the market gap between disposable antigen tests and centralized automated PCR systems,” says Wolfgang Probst, COO and director of XPhyto. “Examples of target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.”

Covid-ID Lab will be available for purchase and delivery in Germany from Max Pharma commencing May 25, 2021, at volume dependent pricing within the range of commonly available COVID-19 PCR test products currently on the market. Initial German manufacturing capacity has been secured with additional manufacturing capacity available based on demand.

Max Pharma is a full-range German pharmaceutical wholesaler in accordance with Section 52a of the German Medicines Act (AMG). Max Pharma supplies pharmacies and clinics throughout Germany with pharmaceuticals, narcotics, and medical products. As announced April 21, 2021, Max Pharma is a licensed distribution, storage and delivery provider for Covid-ID Lab in Germany in addition to fulfilling certain regulatory reporting, notification and logistics obligations.

Parties interested in procuring Covid-ID Lab in Germany or Europe please contact:

Max Pharma GmbH
T: +49 9281 840 160
E: info@max-pharma.de

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.